All In Biotech

Drug Trial Radar · NCT04998812

A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

A Phase IV Multicenter, Open-Label Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

70

Actual

Start

Apr 13, 2022

Primary completion

Apr 8, 2024

Study completion Jul 14, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
PPD Development, LP; Laboratory Corporation of America; Illingworth Research Group
First posted
Aug 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the potential placental transfer of ocrelizumab in pregnant women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) \[in line with the locally approved indications\] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.

Conditions

  • Multiple Sclerosis
  • Clinically Isolated Syndrome

Interventions

  • OcrelizumabDrug

    Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Infants With B Cell Levels (Cluster of Differentiation 19 [CD19+] Cells) Below the Lower Limit of Normal (LLN)Time frame: At Week 6 of infant's life

Locations

11 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • University Of Colorado

    Aurora, Colorado

  • The Ken and Ruth Davee department of Neurology

    Chicago, Illinois

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Hopital Pierre Wertheimer - Hopital Neurologique

    Bron, France

  • Hôpital de la Pitié Salpétrière

    Paris, France

  • St. Josef Hospital GmbH

    Bochum, Germany

  • MultipEL Studies - Institut für klinische Studien

    Hamburg, Germany

  • Hosp. Clinico San Carlos

    Madrid, Spain

  • Universitätsspital Basel

    Basel, Switzerland

  • Inselspital Bern

    Bern, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.